ClinicalTrials.gg
RecruitingNCT07547696Updated Jun 23, 2026

CARRII Native Intervention Optimization Trial

An interventional study of CARRII Native Cores in Fetal Alcohol Spectrum Disorders, Pregnancy and Alcohol-Related Disorders, sponsored by University of Virginia. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 44 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by University of Virginia · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
512
Allocation
Randomized
Ages
18 Years to 44 Years
Sex
Female
01

Study summary

The purpose of this study is to identify the best combination of new intervention components to use with CARRII, the first automated online intervention for alcohol-exposed pregnancies (AEP). This intervention is specifically designed for Native women and others who can become pregnant. Our goal is to maximize the effectiveness of the online intervention while keeping costs manageable for Native communities.

Read the detailed description

In this protocol, for Aim 3, investigators will conduct a large 3-month factorial experiment with 512 participants. This design will identify the optimal intervention that efficiently balances AEP risk reduction with community-informed sustainable cost. Investigators will conduct exploratory analyses of mediation/moderation and identify study feasibility metrics (rates of Native women with AEP risk, and completing study recruitment, baseline, intervention, and follow-up vs. dropout) for a subsequent randomized control trial (RCT).

02

Conditions studied

  • Fetal Alcohol Spectrum Disorders
  • Pregnancy
  • Alcohol-Related Disorders
  • Drinking, Alcohol
  • Contraception Behavior
  • Alcohol Exposed Pregnancy
  • Sexual Behavior

Keywords

  • Native American
  • female
  • adult
  • contraception
  • alcohol
  • digital intervention
  • mobile health (mHealth)
  • optimization
  • risk reduction
03

In context

Fetal Alcohol Spectrum Disorders

65 studies on the registry are indexed under Fetal Alcohol Spectrum Disorders; 13 are open to participants now.

This study's planned enrollment of 512 is above the median of 74 across 57 interventional studies indexed under Fetal Alcohol Spectrum Disorders.

Browse Fetal Alcohol Spectrum Disorders studies →

Lead sponsor

University of Virginia is the lead sponsor of 675 studies on the registry; 138 are open to participants now.

Of its 61 completed or terminated interventional studies of FDA-regulated products, 42 (69%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 44 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Native American/American Indian/Alaska Native,
  • who are not surgically sterile,
  • who report alcohol consumption at risk levels and risk for pregnancy in the past 90 days due to having sex with a man with inconsistent, ineffective, or no .
  • Participants must have access to the Internet via a mobile device they can access daily

Exclusion criteria

Exclusion Criteria:

  • cognitive disorders including mental retardation, dementia, or psychotic disorders that could impair ability to understand the intervention material or give .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
512 participants (estimated)

Study arms

  • Other
    1. New intervention components: All Off

    CARRII Cores New intervention components: All Off

    Other: CARRII Native Cores

  • Other
    2. New intervention components: C

    CARRII Cores New intervention components: C

    Other: CARRII Native Cores

  • Other
    3. New intervention components: B

    CARRII Cores New intervention components: B

    Other: CARRII Native Cores

  • Other
    4. New intervention components: B and C

    CARRII Cores New intervention components: B and C

    Other: CARRII Native Cores

  • Other
    5. New intervention components: A

    CARRII Cores New intervention components: A

    Other: CARRII Native Cores

  • Other
    6. New intervention components: A and C

    CARRII Cores New intervention components: A and C

    Other: CARRII Native Cores

  • Other
    7. New intervention components: A and B

    CARRII Cores New intervention components: A and B

    Other: CARRII Native Cores

  • Other
    8. New intervention components: A, B, and C

    CARRII Cores New intervention components: A, B, and C

    Other: CARRII Native Cores

Interventions

  • OtherCARRII Native Cores

    4 Cores plus combination of 0, 1, 2, or 3 additional components

06

What researchers measure

Primary outcomes

  1. Rate of Alcohol Exposed Pregnancy (AEP) Risk

    The primary outcome will be risk of alcohol-exposed pregnancy in the past month, at the 3 Month (3M) follow-up via daily diary reporting of alcohol consumption, intercourse and contraception use. AEP risk is defined as 1) had vaginal sex with a male during the past 4 weeks, 2) drank alcohol at risk levels during the past 30 days (For women, risky alcohol use is drinking more than 7 standard drinks per week, or more than 3 standard drinks per occasion, or both), 3) past month intermittent or no contraception, and 4) not being sterile and not having a partner (or partners) known to be sterile.

    Time frame: 3 months

Secondary outcomes

  1. Rate of risky alcohol use

    This outcome will measure the rate of risky alcohol use in the past month, at 3 months follow-up via daily diary reporting. For women, risky alcohol use is drinking more than 7 standard drinks per week, or more than 3 standard drinks per occasion, or both.

    Time frame: 3 months

  2. Rate of risky contraception

    This outcome will measure the rate of risky contraception use in the past month, at 3 months follow-up via daily diary reporting. Risky contraception occurs when a fertile woman has sexual intercourse with a man without contraception, or using only ineffective methods, or using an effective method incorrectly or intermittently

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
  • University of Virginia Fontaine Research Park
    Charlottesville, Virginia 22908, United States
    Recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — This project will generate electronic, de-identified data that will be placed in a readily accessible public database of NIAAA data, which is managed in the NIMH Data Archive. Investigators will comply with all data sharing procedures specified by NIAAA and follow procedures described in the National Institute of Mental Health (NIMH) Data Archive (NDa) Sharing summary of tasks and expectations.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: 12 months after data analysis is completed, investigators will deposit it in the data archive

Access criteria: Other researchers can request data from the NIAAA Data Archive using their procedures.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2028, 24 months after the start.

Of 28 interventional studies with no phase under Fetal Alcohol Spectrum Disorders, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 24 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2026
First posted
Apr 23, 2026
StartActual
Jun 2, 2026
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jul 30, 2028
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07547696
Responsible party
Lee M Ritterband (Professor Psychiatry and NB Sciences, University of Virginia) — Principal investigator
First posted
Apr 23, 2026
Start date
Jun 2, 2026
Primary completion
Jun 30, 2028 (estimated)
Completion
Jul 30, 2028 (estimated)
Last update
Jun 23, 2026

Study contacts

Silvia P Park, BA
Contact
spp2d@uvahealth.org
855-488-2227
Karen S Ingersoll, PhD
principal investigator · University of Virginia
Lee M Ritterband, PhD
principal investigator · University of Virginia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion